Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 33

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 33
---
 among other things:

| • |     | reviewing, evaluating and advising the Board on the overall strategy, direction and effectiveness of the Company’s research and development programs and related investments; |

| • |     | providing feedback and analysis to Company management and personnel regarding, and assisting the Board regarding its oversight of, pre-clinical and clinical decision-making; |

| • |     | evaluating and advising the Board and management on the soundness, competitiveness and risks associated with products, programs and technologies in which the Company is, or is considering, investing its efforts; and |

| • |     | reviewing and advising the Board on the Company’s current and potential internal and external programs and investments in science and technology. |

The members of our Science and Technology Committee are Dr. Simson, Dr. Kaplan, Dr. McCracken, Dr. Moran and Dr. Rothenberg. Dr. Simson serves as the Chairperson of the committee. The Science and Technology Committee operates under a written charter, which the Science and Technology Committee will review and evaluate periodically. The Science and Technology Committee met four (4) times during 2024. 21

Executive and Director Compensation Overview Our named executive officers for 2024, which consist of each person who served as our principal executive officer during 2024 and our next two most highly compensated executive officers who were serving as executive officers at the end of 2024, were:

| • |     | Todd Harris, Ph.D., Chief Executive Officer; |

| • |     | Douglas Warner, M.D., Chief Medical Officer; and |

| • |     | Daniel Bensen, Chief Operating Officer. |

The following table sets forth information concerning the compensation of our named executive officers for the years ended December 31, 2023 and 2024. 2024 Summary Compensation Table

| Name and Principal Position |     | Year |      |     | Salary 
 ($)    |         |     | Option 
 Awards 
 ($)(1) |           |     | Non-Equity     
 Incentive Plan 
 Compensation   
 ($)(2)         |         |     | All Other    
 Compensation 
 ($)(3)       |     |     | Total |           |
| Todd Harris, Ph.D.          |     |      | 2024 |     |        | 632,700 |     |        | 6,503,016 |     |                | 433,400 |     |              | 950 |     |       | 7,570,066